Belite Bio, Inc (BLTE): Price and Financial Metrics


Belite Bio, Inc (BLTE): $30.26

0.28 (+0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLTE Stock Price Chart Interactive Chart >

Price chart for BLTE

BLTE Price/Volume Stats

Current price $30.26 52-week high $44.70
Prev. close $29.98 52-week low $8.80
Day low $30.26 Volume 1,000
Day high $30.42 Avg. volume 6,708
50-day MA $30.34 Dividend yield N/A
200-day MA $0.00 Market Cap 752.48M

Belite Bio, Inc (BLTE) Company Bio


Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.


BLTE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLTE Latest Social Stream


Loading social stream, please wait...

View Full BLTE Social Stream

Latest BLTE News From Around the Web

Below are the latest news stories about BELITE BIO INC that investors may wish to consider to help them evaluate BLTE as an investment opportunity.

2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023

If so, you should know that investors like you found what they were looking for this year in the biotechnology and medical technology spaces. Shares of Belite Bio (NASDAQ: BLTE) are up about 209% this year. Investors have been piling into this clinical-stage biotechnology company thanks to encouraging early results from its lead candidate, LBS-008.

Yahoo | December 8, 2022

H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE - Research Report), with a price target of $58.00. The company's shares opened today at $27.50.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -29.6% and a 22.28% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Belite Bio, Inc. ADR with a $58.00 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $44.

Howard Kim on TipRanks | November 21, 2022

Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)There are currently no approved treatments for STGD1 and Dry AMDCurrently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1 patients (the “DRAGON” study) is recruiting subjects12-month interim data from t

Yahoo | November 18, 2022

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27th at 11 AM ET SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, will host a key opinion leader (KOL) event with a focus on LBS-008 (aka Tinlarebant), the Company’s lead asset for the treatment of Stargardt Disease

Yahoo | October 20, 2022

H.C. Wainwright Sticks to Its Buy Rating for Belite Bio, Inc. ADR (BLTE)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE - Research Report), with a price target of $58.00. The company's shares closed last Friday at $33.55.Chen covers the Healthcare sector, focusing on stocks such as Veru, Belite Bio, Inc. ADR, and Applied DNA Sciences. According to TipRanks, Chen has an average return of -22.4% and a 26.30% success rate on recommended stocks. Belite Bio, Inc. ADR has an analyst consensus of Moderate Buy, with a price target consensus of $57.50.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $44.70 and a one-year low of $8.80.

Catie Powers on TipRanks | October 3, 2022

Read More 'BLTE' Stories Here

BLTE Price Returns

1-mo 0.90%
3-mo 12.03%
6-mo -1.66%
1-year N/A
3-year N/A
5-year N/A
YTD 0.38%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.607 seconds.